



Toxicological Profile for Di(2-Ethylhexyl)Phthalate (DEHP)

January 2022



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

CS274127-A

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health
and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention



Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease
Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
January 2022	Final toxicological profile released
December 2019	Draft for public comment toxicological profile released
September 2002	Final toxicological profile released
April 1993	Final toxicological profile released
June 1989	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Rae T. Benedict, Ph.D. (Lead)
Sam Keith, M.S., C.H.P.
Hana Pohl, M.D., Ph.D.
Mike Fay, Ph.D.

Kimberly Zaccaria, Ph.D., D.A.B.T.
Heather Carlson-Lynch, M.S., D.A.B.T.
Julie Melia, Ph.D., D.A.B.T.
Deborah Herber, Ph.D.
Parker Honey, M.P.H.
Courtney Hard, B.A.
Mario Citra, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA, Center for Public Health and Environmental Assessment.

PEER REVIEWERS

1. Tee L. Guidotti, M.D., MPH; Retired Chair of the Department of Environmental and Occupational Health and Director of the Division of Occupational Medicine and Toxicology at George Washington University; Affiliate with Risk Sciences International Inc., Silver Spring, Maryland
2. J. E. Klaunig, Ph.D., Fellow ATS, Fellow IATP; Professor, Environmental Health; Professor, School of Public and Environmental Affairs; Indiana University Bloomington; Bloomington, Indiana
3. Emily S. Barrett, Ph.D.; Associate Professor, Department of Epidemiology; Environmental and Occupational Health Sciences Institute; Rutgers School of Public Health; Piscataway, New Jersey

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS	vii
LIST OF FIGURES	ix
LIST OF TABLES	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS	3
1.3 MINIMAL RISK LEVELS (MRLs)	11
CHAPTER 2. HEALTH EFFECTS	15
2.1 INTRODUCTION	15
2.2 DEATH	99
2.3 BODY WEIGHT	100
2.4 RESPIRATORY	115
2.5 CARDIOVASCULAR	117
2.6 GASTROINTESTINAL	123
2.7 HEMATOLOGICAL	124
2.8 MUSCULOSKELETAL	126
2.9 HEPATIC	127
2.10 RENAL	141
2.11 DERMAL	145
2.12 OCULAR	146
2.13 ENDOCRINE	146
2.14 IMMUNOLOGICAL	164
2.15 NEUROLOGICAL	174
2.16 REPRODUCTIVE	176
2.17 DEVELOPMENTAL	216
2.18 OTHER NONCANCER	288
2.19 CANCER	297
2.20 GENOTOXICITY	301
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	312
3.1 TOXICOKINETICS	312
3.1.1 Absorption	312
3.1.2 Distribution	316
3.1.3 Metabolism	320
3.1.4 Excretion	324
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	330
3.1.6 Animal-to-Human Extrapolations	337
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	337
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	343
3.3.1 Biomarkers of Exposure	344
3.3.2 Biomarkers of Effect	346
3.4 INTERACTIONS WITH OTHER CHEMICALS	346

CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION	355
4.1 CHEMICAL IDENTITY	355
4.2 PHYSICAL AND CHEMICAL PROPERTIES	356
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE	357
5.1 OVERVIEW	357
5.2 PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	359
5.2.1 Production	359
5.2.2 Import/Export	361
5.2.3 Use	361
5.2.4 Disposal	362
5.3 RELEASES TO THE ENVIRONMENT	363
5.3.1 Air	365
5.3.2 Water	367
5.3.3 Soil	368
5.4 ENVIRONMENTAL FATE	370
5.4.1 Transport and Partitioning	370
5.4.2 Transformation and Degradation	372
5.5 LEVELS IN THE ENVIRONMENT	373
5.5.1 Air	376
5.5.2 Water	378
5.5.3 Sediment and Soil	379
5.5.4 Other Media	380
5.6 GENERAL POPULATION EXPOSURE	384
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	416
CHAPTER 6. ADEQUACY OF THE DATABASE	420
6.1 Information on Health Effects	420
6.2 Identification of Data Needs	422
6.3 Ongoing Studies	426
CHAPTER 7. REGULATIONS AND GUIDELINES	429
CHAPTER 8. REFERENCES	431
APPENDICES	
APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS	A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR DEHP	B-1
APPENDIX C. USER'S GUIDE	C-1
APPENDIX D. QUICK REFERENCE FOR HEALTH CARE PROVIDERS	D-1
APPENDIX E. GLOSSARY	E-1
APPENDIX F. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	F-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to DEHP	4
1-2. Health Effects Found in Animals Following Oral Exposure to DEHP	5
1-3. Summary of Sensitive Targets of DEHP – Inhalation.....	12
1-4. Summary of Sensitive Targets of DEHP – Oral.....	13
2-1. Overview of the Number of Studies Examining DEHP Health Effects	19
2-2. Levels of Significant Exposure to DEHP – Inhalation.....	23
2-3. Levels of Significant Exposure to DEHP – Oral	86
3-1. Metabolic Pathway of DEHP.....	321
5-1. Number of NPL Sites with DEHP Contamination	357
6-1. Summary of Existing Health Effects Studies on DEHP By Route and Endpoint.....	421

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for DEHP.....	14
2-1. Levels of Significant Exposure to DEHP – Inhalation.....	20
2-2. Levels of Significant Exposure to DEHP – Oral.....	25
2-3. Selected Epidemiological Studies of DEHP Exposure and Body Weight Metrics.....	101
2-4. Selected Epidemiological Studies of DEHP Exposure and Blood Pressure.....	119
2-5. Selected Epidemiological Studies of DEHP Exposure and Serum Lipid/Cholesterol Alterations.....	128
2-6. Summary of Epidemiological Studies of DEHP Exposure and Thyroid Hormone Levels.....	147
2-7. Selected Epidemiological Studies of DEHP Exposure and Allergy, Asthma, and Atopy.....	165
2-8. Summary of Epidemiological Studies of DEHP Exposure and Serum Reproductive Hormones or Leydig Cell Functionality in Adult Men.....	178
2-9. Summary of Epidemiological Studies of DEHP Exposure and Sperm Parameters.....	187
2-10. Summary of Epidemiological Studies of DEHP Exposure and Female Reproductive Effects.....	198
2-11. Summary of Epidemiological Studies of Prenatal DEHP Exposure and Pregnancy Outcomes.....	203
2-12. Summary of Epidemiological Studies of Prenatal DEHP Exposure and Birth Size.....	217
2-13. Summary of Epidemiological Studies of Prenatal DEHP Exposure and BMI, Waist Circumference, and Measures of Adiposity.....	226
2-14. Summary of Epidemiological Studies of Prenatal DEHP Exposure and Selected Neurodevelopmental Outcomes.....	239
2-15. Summary of Epidemiological Studies of Prenatal DEHP Exposure and Reproductive Development in Males.....	256
2-16. Summary of Epidemiological Studies of DEHP Exposure and Reproductive Development in Females.....	276
2-17. Selected Epidemiological Studies of DEHP Exposure and Diabetes or Glucose Homeostasis.....	289
2-18. Genotoxicity of DEHP <i>In Vitro</i>	301
2-19. Genotoxicity of MEHP <i>In Vitro</i>	304
2-20. Genotoxicity of DEHP <i>In Vivo</i>	306
2-21. Genotoxicity of MEHP <i>In Vivo</i>	307

3-1. Tissue Distribution of ¹⁴ C Following an Intravenous Dose of 50 mg/kg [¹⁴ C]-DEHP in Male Wistar Rats	318
3-2. Tissue Distribution of ¹⁴ C Following an Oral Dose of 500 mg/kg [¹⁴ C]-DEHP in Male Wistar Rats	318
3-3. Michaelis-Menten Constants for DEHP Hydrolase Activity in Liver Microsomes	322
3-4. Comparison of Phthalate Metabolites in Urine Following Dosing with DEHP	324
3-5. Blood, Serum, or Plasma Elimination Half-Lives (t _{1/2}) for DEHP and MEHP	326
3-6. Urinary Elimination Half-Lives (t _{1/2}) for DEHP, MEHP, and Metabolites	328
4-1. Chemical Identity of DEHP	355
4-2. Physical and Chemical Properties of DEHP	356
5-1. Facilities that Produce, Process, or Use DEHP	360
5-2. Releases to the Environment from Facilities that Produce, Process, or Use DEHP	364
5-3. Lowest Limit of Detection Based on Standards	375
5-4. Summary of Environmental Levels of DEHP	375
5-5. DEHP Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	376
5-6. Concentration of DEHP in Food	380
5-7. Mean and Median Values of DEHP in Food	381
5-8. Concentration DEHP in Categories of Household Waste	384
5-9. Uncorrected Urinary MEHP Concentrations for the U.S. Population from NHANES 1999–2014	386
5-10. Creatinine-Corrected Urinary MEHP Concentrations for the U.S. Population from NHANES 1999–2014	389
5-11. Uncorrected Urinary MEHHP Concentrations for the U.S. Population from NHANES 2001–2014	392
5-12. Creatinine-Corrected Urinary MEHHP Concentrations for the U.S. Population from NHANES 2001–2014	395
5-13. Uncorrected Urinary MEOHP Concentrations for the U.S. Population NHANES 2001–2014	398
5-14. Creatinine-Corrected Urinary MEOHP Concentrations for the U.S. Population from NHANES 2001–2014	401
5-15. Uncorrected Urinary MECPP Concentrations for the U.S. Population from NHANES 2003–2014	404

5-16. Creatinine Corrected MECPP Concentrations for the U.S. Population from NHANES 2003–2014	407
5-17. FDA Estimates of DEHP Exposures Resulting from Medical Treatments	418
6-1. Ongoing Studies on DEHP	427
7-1. Regulations and Guidelines Applicable to DEHP	429